Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07808333) titled 'Nicotinamide for Retinal Protection in Primary Open-Angle Glaucoma (NADIR Trial)' on Sept. 2.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: University of Chicago
Condition:
Glaucoma, Open-angle
Primary Open Angle Glaucoma (POAG)
Intervention:
Drug: Nicotinamide
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: June 1, 2027
Target Sample Size: 96
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/study/NCT0780...